Navigation Links
Sigma-Aldrich Announces Organizational Changes
Date:2/16/2011

ST. LOUIS, Feb. 16, 2011 /PRNewswire/ -- Sigma-Aldrich® Corporation (Nasdaq: SIAL) announces the following executive leadership appointments intended to more closely align its corporate structure with its strategic plan.

Frank Wicks, President Research, will assume responsibility for the entire portfolio of Research products, including those in Research Essentials, Research Specialties and Research Biotech.  This newly combined Research strategic business unit will be responsible for product development and R&D; strategic marketing and branding; and global sourcing and operations strategies.  This new organization will better enable the Company to accelerate strategic initiatives in defined key areas of focus: Analytical, Biology and Chemistry with an added emphasis on the fast growing materials science market.  Wicks will continue to report to the CEO, Rakesh Sachdev.

David Smoller, formerly President Research Biotech, has been appointed Chief Scientific Officer reporting to Frank Wicks. In this new role, Smoller will be responsible for developing a global R&D strategy and footprint for all research and development initiatives as well as managing our intellectual property portfolio and licensing activity.  He will continue to be responsible for developing and commercializing innovative products in emerging technologies of Biology and will leverage his successes in bringing new technologies to market in the area of materials science.  

Gerrit van den Dool has been promoted to Vice President and Managing Director US and Canada Region.  He will have responsibility for the execution of our Research business strategy as well as supporting the SAFC business in US/Canada including sales, service, distribution, manufacturing and compliance.  Prior to relocating from Germany to the US in 2007 to head-up North America sales and Global Accounts, van den Dool successfully led European Sales and Operations.  Mike Harris and Eric Green will continue as Vice Presidents and Managing Directors of the Europe, Middle East, Africa (EMEA) and International regions, respectively, and, with van den Dool, will report to the CEO.

Gilles Cottier, President SAFC, will continue to lead the global SAFC organization and report to the CEO. Cottier and his team are responsible for developing and executing the global strategies to enhance the bio-science, custom Pharma, high-tech and supply solutions businesses.

Rakesh Sachdev, President and CEO, stated, "We expect this new organization to significantly enhance the organic growth of our core Research and SAFC businesses.  This proven leadership team is best situated to execute the key legs of our growth strategy while driving operational excellence and deploying our financial strength to boost growth through acquisitions."

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, and as key components in pharmaceutical, diagnostic and other high technology manufacturing.  We have customers in life science companies, university and government institutions, hospitals and in industry.  Over one million scientists and technologists use our products.  Sigma-Aldrich operates in 40 countries and has 7,900 employees providing excellent service worldwide.  We are committed to accelerating our Customers' success through leadership in Life Science, High Technology and Service.  For more information about Sigma-Aldrich, please visit our award winning web site at www.sigma-aldrich.com.


'/>"/>
SOURCE Sigma-Aldrich Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
3. Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
4. Sigma-Aldrich to Present at the UBS 2008 Global Life Sciences Conference on September 24, 2008
5. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
6. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
7. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
8. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
9. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
10. Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
11. Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. ... company focused on developing and commercializing products to treat ... announced today that it will be hosting an Investor ... ET on the origins of innate defense regulators (IDRs) ... review of oral mucositis and the recently announced and ...
(Date:12/8/2016)... 8, 2016   Biocept, Inc . (NASDAQ: ... of clinically actionable liquid biopsy tests to improve ... data featuring its Target Selectorâ„¢ Circulating Tumor Cell ... the detection of actionable biomarkers in patients with ... by Sara Cannon Research Institute (SCRI), the research ...
(Date:12/7/2016)... , Dec. 7, 2016 /PRNewswire/ - OncoQuest Inc. ... and commercialization of immunotherapeutic products for the treatment ... into an Antibody Manufacturing Development Program with Cytovance ... USA) for its oregovomab antibody product. Supported by ... IIb clinical study in ovarian cancer patients, OncoQuest ...
(Date:12/7/2016)... , Dec. 7, 2016  Vyriad Inc. announced today ... the company,s Board of Directors. "We are ... build our business and develop our oncolytic viruses as ... said Stephen Russell , MD, PhD, CEO of ... share our vision and passion for making a difference ...
Breaking Biology Technology:
(Date:11/29/2016)... -- BioDirection, a privately held medical device company developing ... of concussion and other traumatic brain injury (TBI), announced ... with the U.S. Food and Drug Administration (FDA) to ... the meeting company representatives reviewed plans for clinical development ... of a planned pilot trial. "We ...
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/19/2016)... Nov. 18, 2016 Securus Technologies, a leading ... public safety, investigation, corrections and monitoring, announced today that ... ICSolutions, to have an independent technology judge determine who ... modern high tech/sophisticated telephone calling platform, and the best ... they do most of what we do – which ...
Breaking Biology News(10 mins):